@article{JTD2669,
author = {Muharrem Kiskac and Mehmet Zorlu and Muhammed Emin Akkoyunlu and Elif Kilic and Cumali Karatoprak and Mustafa Cakirca and Erdinc Yavuz and Cuneyt Ardic and Ahmet Adil Camli and Mehmetali Cikrikcioglu and Levent Kart},
title = {Vaspin and lipocalin-2 levels in severe obsructive sleep apnea},
journal = {Journal of Thoracic Disease},
volume = {6},
number = {6},
year = {2014},
keywords = {},
abstract = {Background: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS and examine the relationship between these two adipocytokines and OSAS.
Methods: The study consisted of two groups: severe OSAS patients with an apnea-hypopnea index (AHI) of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group, 25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared.
Results: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13; P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17).
Conclusions: We found that serum vaspin levels were significantly lower in patients with severe OSAS compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in severe OSAS patients may be important in diagnosis and follow-up of these patients.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/2669}
}